Skip to content
Home » Cytomedix Q4 2013 Earnings Results Conference Call Transcript (Presentation)

Cytomedix Q4 2013 Earnings Results Conference Call Transcript (Presentation)


Good day ladies and gentlemen and welcome to the Quarter 4 2013 Cytomedix earnings conference call. My name is Caroline and I will be your operator for today. (Operator Instructions).

And now I would like to turn the call over to Mr. Michael Wood, Managing Director of LifeSci Advisors. Please go ahead.

Michael Wood – Managing Director of LifeSci Advisors

Good morning. This is Michael Wood with LifeSci Advisors. I’d like to thank you for participating today’s Cytomedix fourth quarter 2013 earnings conference call. Joining me from the company this morning are Martin Rosendale, Chief Executive Officer; Steve Shallcross, Chief Financial Officer and Dean Tozer, Chief Commercial Officer.

Here is an outline for today’s call. First, Marty will provide an update on the recent Deerfield financing announced last night, AutoloGel launch initiatives as well as research and development activities. He will then hand over the call to Steve who will provide you with a summary of fourth-quarter and full-year 2013 financial results. Then Dean Tozer, newly appointed chief commercial officer of the company will join the call. Finally, Marty will conclude with an outlook for early 2014 before opening the call to questions.

After the market closed yesterday, Cytomedix announced financial results for the fourth quarter and full year 2013. If you have not yet received this newsletter or if you like to be added to the company’s distribution list, please call LifeSci Advisors in New York at 646-597-6992 and speak with Paul Arndt.

Before we begin today’s call, I would like to caution that comments made during the conference call will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Cytomedix. Actual results could differ materially from those projected. I encourage you to review the company’s filings with the Securities and Exchange Commission including without limitation the company’s Forms 10-K, 10-Q including the most recently filed 10-K which identify specific risk factors that may cause actual results or events to differ materially from those described in the forward looking statements.

Furthermore the content of this conference call contains time sensitive information that is accurate only as of the date of this live broadcast Tuesday, April 1, 2014. Cytomedix undertakes no obligations to revise or update any statements that reflect events or circumstances after the date of this conference call.

Pages: First |1 | ... | Next → | Last | View Full Transcript